SCHEMBL2834471

SCHEMBL2834471

C=CCCOC(=O)c1cccc(F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.47
CES1 P23141 1/20 0.47
NPC1 O15118 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
ADRB2 P07550 1/20 0.47
ADRB1 P08588 1/20 0.47
ADRB3 P13945 1/20 0.47
RAB9A P51151 1/20 0.47
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
PARP1 P09874 1/20 0.45
PKM P14618 1/20 0.44
KMT2A Q03164 2/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
BCHE P06276 2/20 0.42
PAX8 Q06710 1/20 0.42
GPR52 Q9Y2T5 1/20 0.42
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835102 0.91 NPC1 (0.46) CES2CES1NPC1TDP1ADRB2
SCHEMBL2831834 0.84 CYP3A4 (0.53) CES2CES1NPC1TDP1ADRB2
SCHEMBL11354226 0.83 CES2 (0.52) CES2CES1NPC1TDP1ADRB2
SCHEMBL24370132 0.82 CES2 (0.53) CES2NPC1ADRB1RAB9AKMT2A
SCHEMBL28051732 0.82 L3MBTL1 (0.52) NPC1TDP1ADRB2ADRB1ADRB3
SCHEMBL2833613 0.81 KMT2A (0.45) CES2CES1TDP1ADRB2ADRB1
SCHEMBL850767 0.81 ADRB2 (0.48) NPC1TDP1ADRB2ADRB1ADRB3
SCHEMBL529612 0.80 TDP1 (0.63) NPC1TDP1RAB9AESR1ESR2
SCHEMBL28953541 0.80 CES2 (0.52) CES2CES1NPC1TDP1ADRB2
SCHEMBL522694 0.80 LMNA (0.64) CES2CES1NPC1TDP1ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 CES2 87/4885CES1 994/4885NPC1 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.